# Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms

Source: https://onco.cc/trials/nct01064466/  
OnCo record `nct01064466` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Etoposide in small-cell lung cancer, run by Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair, active and no longer recruiting.

## Summary

Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms is a phase 2/3 interventional study registered as NCT01064466 by Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair, with 600 participants enrolled, started 2025-07-16 and due to reach its primary completion in 2026-11-18. Interventions recorded: ETOPOSIDE - Usual and ETOPOSIDE - Study.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01064466
- Phase: 2/3
- Setting: Explore the Relationship Between Single Nucleotide Polymorphisms and Etoposide Response and Toxicity in Patients With Small Cell Lung Cancer.
- Sponsor: Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair
- Enrolled: 600

## Sources

- ClinicalTrials.gov NCT01064466: https://clinicaltrials.gov/study/NCT01064466

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Etoposide](https://onco.cc/drugs/etoposide/)

---
JSON: https://onco.cc/api/v1/entities/nct01064466.json